IMBdx Overview

  • Year Founded
  • 2018

Year Founded

  • Status
  • Public

  • Employees
  • 60

Employees

  • Stock Symbol
  • 461030

Stock Symbol

  • Share Price
  • $1.65
  • (As of Friday Closing)

IMBdx General Information

Description

IMBdx Inc detects and analyzes the genomic profile of tumor DNA with a single draw of blood. It provides personalized and optimized analysis information that can be utilized in therapy selection and monitoring. Its AlphaLiquid platform offers ctDNA-based precision diagnostics solutions across the full continuum of cancer care, from therapy selection (AlphaLiquid 100/HRR) to recurrence and minimal residual disease(MRD) monitoring (CancerDetect), and multi-cancer early detection (CancerFind). Its services are Clinical Service BioPharma, Research, and Healthcare Checkup.

Contact Information

Website
www.imbdx.com
Ownership Status
Publicly Held
Financing Status
Formerly VC-backed
Corporate Office
  • 131 Gasan Digital 1-ro, Geumcheon-gu
  • 21st Floor, Building A, BYC High City Building
  • Seoul, 08506
  • South Korea
+82
Primary Industry
Drug Discovery
Other Industries
Pharmaceuticals
Biotechnology
Stock Exchange
KRX
Corporate Office
  • 131 Gasan Digital 1-ro, Geumcheon-gu
  • 21st Floor, Building A, BYC High City Building
  • Seoul, 08506
  • South Korea
+82

Want detailed data on 11M+ companies?

What you see here scratches the surface

Request a free trial

Want to dig into this profile?

We’ll help you find what you need

Learn more

IMBdx Stock Performance

As of 20-Nov-2026, IMBdx’s stock price is $1.65. Its current market cap is $23.7M with 14.3M shares.

(As of Friday Closing)

Stock Price Previous Close 52 wk Range Market Cap Shares Average Volume EPS
$1.65 $1.60 $1.32 - $8.78 $23.7M 14.3M 16.8K -$0.37

IMBdx Financials Summary

As of 30-Jun-2026, IMBdx has a trailing 12-month revenue of $3.86M.

In Thousands,
USD
TTM 30-Jun-2026 FY 2025 31-Dec-2025 FY 2024 31-Dec-2024 FY 2023 31-Dec-2023
EV 20,967 80,531 81,131
Revenue 3,858 3,744 2,497 3,080
EBITDA (4,609) (5,007) (6,439) (6,149)
Net Income (5,229) (5,575) (7,019) (7,967)
Total Assets 15,973 18,833 23,115 7,621
Total Debt 205 304 294 249
Public Fundamental Data provided by Morningstar, Inc. disclaimer

IMBdx Valuation & Funding

Deal Type Date Amount Valuation/
EBITDA
Post-Val Status Debt

This information is available in the PitchBook Platform. To explore IMBdx‘s full profile, request access.

Request a free trial

IMBdx Comparisons

Description
Primary
Industry
HQ Location
Employees
Total Raised
Post Valuation
Last
Financing
Details
IMBdx Inc detects and analyzes the genomic profile of tumor DNA with a single draw of blood. It provides personalized an
Drug Discovery
Seoul, South Korea
60 As of 2025

Menlo Park, CA
 

Yongin-si, South Korea
 
Add Comparison

PitchBook’s comparison feature gives you a side-by-side look at key metrics for similar companies. Personalize which data points you want to see and create visualizations instantly.

Request a free trial

IMBdx Competitors (6)

One of IMBdx’s 6 competitors is GRAIL, a Formerly VC-backed company based in Menlo Park, CA.

Company Name Financing Status Location Employees Total Raised Last Financing Date/Type Last Financing Amount
GRAIL Formerly VC-backed Menlo Park, CA
GC Genome Corporation Yongin-si, South Korea
Foundation Medicine Formerly VC-backed Boston, MA
Freenome Formerly VC-backed Brisbane, CA
Guardant Health Formerly VC-backed Palo Alto, CA
To view IMBdx’s complete competitors history, request access »

IMBdx Patents

IMBdx Recent Patent Activity

Publication ID Patent Title Status First Filing Date Technology (CPC) Citations
WO-2026197667-A1 Early cancer screening method using methylation signal and information provision device using same Pending 18-Mar-2025
EP-4282984-A1 Method for construction of multi-feature prediction model for cancer diagnosis Pending 29-Mar-2022
EP-4282984-A4 Method for construction of multi-feature prediction model for cancer diagnosis Pending 29-Mar-2022
WO-2023191197-A1 Method for construction of multi-feature prediction model for cancer diagnosis Inactive 29-Mar-2022
EP-4287213-A1 Method for predicting cancer recurrence using patient-specific panel Pending 29-Mar-2022 C12Q1/6886
To view IMBdx’s complete patent history, request access »

IMBdx Signals

Growth Rate

Weekly
Growth
Weekly Growth

Size Multiple

Median
Size Multiple

Key Data Points

Similarweb Unique Visitors

Majestic Referring Domains

PitchBook’s non-financial metrics help you gauge a company’s traction and growth using web presence and social reach.

Request a free trial

IMBdx Investors

Investor Name Investor Type Holding Investor Since Participating Rounds Contact Info

This information is available in the PitchBook Platform. To explore IMBdx‘s full profile, request access.

Request a free trial

IMBdx ESG

Peers Analysis

Peer performance insights compare the company’s ESG performance to the performance of selected peers to help inform future ESG decisions and drive internal performance improvements.

Global

Covered Companies

Rank

Percentile

Pharmaceuticals

Industry

Rank

Percentile

Biotechnology

Subindustry

Rank

Percentile

To view IMBdx’s complete esg history, request access »

IMBdx FAQs

  • When was IMBdx founded?

    IMBdx was founded in 2018.

  • Where is IMBdx headquartered?

    IMBdx is headquartered in Seoul, South Korea.

  • What is the size of IMBdx?

    IMBdx has 60 total employees.

  • What industry is IMBdx in?

    IMBdx’s primary industry is Drug Discovery.

  • Is IMBdx a private or public company?

    IMBdx is a Public company.

  • What is IMBdx’s stock symbol?

    The ticker symbol for IMBdx is 461030.

  • What is the current stock price of IMBdx?

    As of 20-Nov-2026 the stock price of IMBdx is $1.65.

  • What is the current market cap of IMBdx?

    The current market capitalization of IMBdx is $23.7M.

  • What is IMBdx’s current revenue?

    The trailing twelve month revenue for IMBdx is $3.86M.

  • Who are IMBdx’s competitors?

    GRAIL, GC Genome, Foundation Medicine, Freenome, and Guardant Health are some of the 6 competitors of IMBdx.

  • What is IMBdx’s annual earnings per share (EPS)?

    IMBdx’s EPS for 12 months was -$0.37.

Data Transparency

  • Meet our data hygiene team

    Discover how our experts ensure you’re getting the most accurate financial data in the industry.

    Read more
  • How PitchBook sources data

    Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.

    Discover our process